C4X Discovery adds business and legal expertise to board

C4X Discovery on Wednesday appointed Eva-Lotta Allan and Natalie Walter to the roles of non-executive chairman of the board and non-executive director, respectively.

The AIM-traded drug discovery company said Allan, who has over three decades of experience in the healthcare industry, was most recently chief business officer at Immunocore, where she played an "instrumental role" in the $320m fundraising in 2015.

Allan has previously served in senior positions at Ablynx NV, Vertex Pharmaceuticals (Europe), Oxford Asymmetry International, Oxford Glycosciences and Amersham International.

Currently, she serves as non-executive director of Oslo listed company, Targovax ASA and is a non-executive director of Crescendo Biologics.

Clive Dix, chief executive of C4X Discovery, said: "I am very pleased to welcome Eva-Lotta and Natalie to the board. They are both highly experienced leaders in the life sciences sector with outstanding track records across business and strategy development, legal and finance, as well as capital market transactions."

Natalie Walter, the company’s newly appointed non-executive director, is a corporate finance lawyer with more than 20 years of experience advising on international equity capital markets transactions in the healthcare sector.

She currently consults as general counsel to Oxford BioMedica and was an equity partner at Covington & Burling, Morrison & Foerster and director and legal counsel on the ECM desk at Lehman Brothers.

Natalie Walter, incoming non-executive director of C4X Discovery, said: "C4X Discovery's business model, ambition and high-quality team make for a compelling proposition for investors and I look forward to being part of the company's ongoing development and future success."

Elsewhere, Sam Williams, interim chairman of the board, has stepped down from the role and from the board to focus on his other business interests.

As of 1413 BST, C4X Discovery’s shares were up 1.05% at 96.00p.